Signalingcomponents of human epidermal growth factor receptor 2(HER2), epithelial growth factor receptor (EGFR), andprogrammed death receptor-1 (PD-1) are among thesetherapeutic targets that have led to successful development ofmolecular marker-driven cancer therapy (Figure 2). This evidence concerns the gene ERBB2 and cancer.